Press Releases
– Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant – Neutralizing antibody level against Omicron is approximately 1/3 of the comparable antibody level against the original Corona Virus – Ten of 13 tested patients vaccinated during phase 2 trials demonstrated measurable level of…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment…
Read More
Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies Excerpt from the Press Release: SAN DIEGO, Jan. 26, 2022 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in…
Read More
Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companies COVAXIN™ (BBV152), if approved, to be the first product manufactured in new upgraded facility New facility includes potential for manufacturing for breakthrough gene therapies and serve as R&D hub…
Read More
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV First-in-human trial is now open for enrollment Excerpt from the Press Release: SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced…
Read More
Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s second-largest pharmaceutical market Excerpt from the Press Release: SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye…
Read More
Excerpt from the Press Release: Study met primary endpoint with 47.4% objective response rate Safety and tolerability profile consistent with previously reported data Planned BLA submission on track for later this year Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Checkpoint…
Read More
Excerpt from the Press Release: STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans. SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today…
Read More
Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study…
Read More
Agreement will leverage Iterative Scopes powerful machine learning and AI computational tools together with Janssen’s data science expertise to enhance clinical trials for Inflammatory Bowel Disease. Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in the development of precision-based gastrointestinal disease technologies, announced today that it has entered into a collaboration with…
Read More